Pharmacotherapies for alcohol abuse. Withdrawal and treatment
- PMID: 9222259
- DOI: 10.1016/s0025-7125(05)70554-x
Pharmacotherapies for alcohol abuse. Withdrawal and treatment
Abstract
Pharmacologic management of alcoholism is only one part of the management of both alcohol dependence and withdrawal, which also includes the provision of a calm, quiet environment; reassurance; ongoing reassessment; attention to fluid and electrolyte disorders; treatment of coexisting addictions and common medical, surgical, and psychiatric comorbidities; and referral for ongoing psychosocial and medical treatment. For further discussion of these topics, the reader is referred to previously published sources. A survey of alcoholism treatment programs revealed that although benzodiazepines were the most commonly used drugs, standardized monitoring of patients' withdrawal severity was not common practice, and a significant minority of clinicians were using a variety of other drugs, some not known to prevent or treat the complications of withdrawal. Treatment should be based on the available evidence (Working Group on Pharmacological Management of Alcohol Withdrawal: American Society of Addiction Medicine Committee on Practice Guidelines: Pharmacological management of alcohol withdrawal: An evidence-based practice guideline. Unpublished draft, 1997). Patients with significant symptoms, patients with complications such as seizures or delirium tremens, and patients at higher risk for complications of alcohol withdrawal should receive benzodiazepines, particularly chlordiazepoxide, diazepam, or lorazepam, because of their safety and documented efficacy in preventing and treating the most serious complications of alcohol withdrawal. These drugs may be dosed on a fixed schedule for a predetermined number of doses on a tapering schedule over several days, or they may be administered by front-loading. An alternative approach for selected patients without seizures or acute comorbidity is symptom-triggered therapy, which individualizes treatment and decreases the duration and dose of medication administration. With either of the regimens, patients should have their withdrawal severity monitored until symptoms are resolving. Once withdrawal from alcohol is safely completed, the focus should turn to helping to prevent relapse. Disulfiram may be useful in highly motivated subsets of patients and when compliance-enhancing strategies are used. Naltrexone is useful in the broader population of patients entering treatment for alcohol dependence. These pharmacologic interventions should be given in the context of ongoing psychosocial support. There is substantial evidence that pharmacologic management of alcohol abuse and dependence is effective. As would be predicted from alcohol's myriad cellular effects, no panacea exists for alcoholism. For alcohol withdrawal, however, although treatment regimens have only recently been refined, evidence for effective treatment of symptoms and prevention of complications with benzodiazepines has been available for decades. Within the last decade, effective treatments, including naltrexone, have been shown to reduce alcohol intake in alcohol-dependent persons. Given the prevalence and cost of alcohol-related problems, all effective therapies (including pharmacologic treatments) should be considered to treat alcohol abuse and dependence.
Similar articles
-
New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.Med J Aust. 2021 Oct 4;215 Suppl 7:S3-S32. doi: 10.5694/mja2.51254. Med J Aust. 2021. PMID: 34601742
-
Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting.Alcohol Alcohol. 2011 May-Jun;46(3):318-23. doi: 10.1093/alcalc/agr020. Epub 2011 Mar 17. Alcohol Alcohol. 2011. PMID: 21414950 Clinical Trial.
-
Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it.Prescrire Int. 2007 Feb;16(87):24-31. Prescrire Int. 2007. PMID: 17323538
-
[Assessment and Treatment of Alcohol Withdrawal Syndrome].Korean J Gastroenterol. 2020 Aug 25;76(2):71-77. doi: 10.4166/kjg.2020.76.2.71. Korean J Gastroenterol. 2020. PMID: 32839369 Review. Korean.
-
Treatment of Severe Alcohol Withdrawal.Ann Pharmacother. 2016 May;50(5):389-401. doi: 10.1177/1060028016629161. Epub 2016 Feb 9. Ann Pharmacother. 2016. PMID: 26861990 Review.
Cited by
-
Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study.EClinicalMedicine. 2023 Jun 22;61:102046. doi: 10.1016/j.eclinm.2023.102046. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37415844 Free PMC article.
-
Phenobarbital-Based Protocol for Alcohol Withdrawal Syndrome in a Medical ICU: Pre-Post Implementation Study.Crit Care Explor. 2023 Apr 18;5(4):e0898. doi: 10.1097/CCE.0000000000000898. eCollection 2023 Apr. Crit Care Explor. 2023. PMID: 37091477 Free PMC article.
-
Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder.Front Psychiatry. 2021 Nov 30;12:781668. doi: 10.3389/fpsyt.2021.781668. eCollection 2021. Front Psychiatry. 2021. PMID: 34916977 Free PMC article. Review.
-
Inpatient Addiction Consult Service: Expertise for Hospitalized Patients with Complex Addiction Problems.Med Clin North Am. 2018 Jul;102(4):587-601. doi: 10.1016/j.mcna.2018.03.001. Med Clin North Am. 2018. PMID: 29933817 Free PMC article. Review.
-
Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.Eur J Clin Pharmacol. 2016 Jul;72(7):807-12. doi: 10.1007/s00228-016-2061-x. Epub 2016 Apr 20. Eur J Clin Pharmacol. 2016. PMID: 27099220 Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials